Phase II Trial of Subcutaneous Injections of Interleukin-2 for the Treatment of Mycosis Fungoides or the Sezary Syndrome
- Determine the response rate in patients with mycosis fungoides or Sezary syndrome
treated with interleukin-2 (IL-2).
- Determine the toxicity of this regimen in these patients.
OUTLINE: This is a multicenter study.
Patients receive interleukin-2 subcutaneously for 4 consecutive days a week for 6
consecutive weeks. Treatment repeats every 8 weeks in the absence of disease progression or
unacceptable toxicity. Patients who achieve complete response or stable disease continue
treatment for 2 courses past best response. Patients who demonstrate a persistent partial
response continue treatment in the absence of disease progression or unacceptable toxicity.
Patients are followed every 3 months for survival.
PROJECTED ACCRUAL: A total of 15-35 patients will be accrued for this study.
Primary Purpose: Treatment
Timothy M. Kuzel, MD
Robert H. Lurie Cancer Center
United States: Federal Government
|Robert H. Lurie Comprehensive Cancer Center, Northwestern University||Chicago, Illinois 60611|
|Boston Medical Center||Boston, Massachusetts 02118|